Timing of carbetocin administration in vaginal deliveries: a double-blind, randomized controlled trial.
Administering carbetocin before placental delivery may reduce the incidence of postpartum hemorrhage, but it is associated with a higher rate of manual placenta removal.
Where it sits
this study against the rest of the carbetocin corpusSummary and findings
This study compared the efficacy of administering carbetocin before versus after placental delivery in preventing postpartum hemorrhage (PPH) among 160 primiparous women with uncomplicated pregnancies. Participants received 100 μg of carbetocin either before or after placental delivery. The results indicated a lower incidence of PPH in the carbetocin-before group compared to the carbetocin-after group.
Abstract
Objectives This study aimed to compare the efficacy of administering carbetocin before vs. after placental delivery in preventing postpartum hemorrhage (PPH) in low-risk vaginal deliveries. Methods The randomized controlled trial was conducted at Kartal City Hospital, Istanbul, Turkey. A total of 160 primiparous women with uncomplicated pregnancies who underwent vaginal delivery were enrolled. Participants were randomly assigned to receive 100 μg of carbetocin either before or after placental delivery. The primary outcome was the incidence of PPH. Secondary outcomes included the need for additional uterotonics, manual removal of the placenta with consequent antibiotic administration, blood transfusions, maternal adverse events, and changes in hemoglobin levels at baseline and 24 h postpartum. Results The incidence of PPH was significantly lower in the carbetocin-before group than in the carbetocin-after group (p=0.015). The carbetocin-before group had a significantly lower mean hemoglobin drop compared to the carbetocin-after group (p<0.001). The need for additional uterotonics was significantly higher in the carbetocin-after group (p<0.001). Manual placenta removal and the need for antibiotics were more frequent in the carbetocin-before group (p=0.017). No significant differences in adverse maternal events were observed between the groups. Conclusions Administering carbetocin before placental delivery significantly reduces the incidence of PPH, blood loss, and the need for additional uterotonics. However, the increased rate of manual placenta removal necessitates individualized risk-benefit assessment; pre-placental administration may be most advantageous in women at elevated risk for PPH, in whom the hemorrhagic benefit outweighs the risks associated with manual extraction.
Background
This paper addresses the clinical question of the optimal timing for carbetocin administration during vaginal deliveries to prevent postpartum hemorrhage (PPH). Prior studies have suggested that carbetocin can reduce PPH, but the timing of administration has not been thoroughly investigated. This study is significant as it aims to clarify whether administering carbetocin before or after placental delivery is more effective in low-risk populations.
Methods
The study was a double-blind, randomized controlled trial conducted at Kartal City Hospital, Istanbul, Turkey. A total of 160 primiparous women with uncomplicated pregnancies were enrolled and randomly assigned to receive 100 μg of carbetocin either before or after placental delivery. The primary outcome was the incidence of PPH, with secondary outcomes including the need for additional uterotonics, manual removal of the placenta, blood transfusions, maternal adverse events, and changes in hemoglobin levels at baseline and 24 hours postpartum.
Results
The incidence of PPH was significantly lower in the carbetocin-before group compared to the carbetocin-after group (p=0.015). Additionally, the mean hemoglobin drop was significantly lower in the carbetocin-before group (p<0.001). The need for additional uterotonics was significantly higher in the carbetocin-after group (p<0.001). Manual placenta removal was more frequent in the carbetocin-before group (p=0.017). No significant differences in adverse maternal events were observed between the groups.
Interpretation
The findings suggest that administering carbetocin before placental delivery may be more effective in reducing PPH compared to after delivery. However, the clinical significance of the findings should be evaluated in the context of the increased rate of manual placenta removal associated with pre-placental administration. Limitations such as the single-site nature of the study and potential confounding factors related to manual extraction may affect the conclusions drawn.
Key findings
- Incidence of PPH was significantly lower in the carbetocin-before group than in the carbetocin-after group (p=0.015).
- Mean hemoglobin drop was significantly lower in the carbetocin-before group compared to the carbetocin-after group (p<0.001).
- Need for additional uterotonics was significantly higher in the carbetocin-after group (p<0.001).
- Manual placenta removal and need for antibiotics were more frequent in the carbetocin-before group (p=0.017).
- No significant differences in adverse maternal events were observed between the groups.
Limitations
- Single-site study may limit generalizability.
- Sample size of 160 may not capture all variability.
- Potential confounding factors related to manual placenta removal.
- Short follow-up period of 24 hours postpartum.